Market Cap 695.27M
Revenue (ttm) 85.21M
Net Income (ttm) -140.11M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -164.43%
Debt to Equity Ratio 0.00
Volume 1,073,700
Avg Vol 893,730
Day's Range N/A - N/A
Shares Out 52.28M
Stochastic %K 71%
Beta 2.75
Analysts Strong Sell
Price Target $28.50

Company Profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macu...

Industry: Biotechnology
Sector: Healthcare
Phone: 510 505 2680
Address:
5858 Horton Street, Suite 455, EmeryVille, United States
LMARB
LMARB Jul. 1 at 3:19 PM
$FDMT wonder what this will avg after 2 year follow up presentation in 3 weeks
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:52 PM
$FDMT Got cute and swung one too many times...oh well. I'll take a long position once this cools off.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:04 PM
$FDMT RSI of 77? It's been a long time since it's seen that kind of strength.
0 · Reply
Doozio
Doozio Jun. 30 at 2:20 AM
$FDMT ENTA 🐒🍌🧠⏰♾️
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 12:04 AM
$FDMT https://www.statnews.com/2026/06/29/vijay-kumar-exits-fda-office-of-therapeutic-products/
1 · Reply
StonkMethod
StonkMethod Jun. 29 at 6:58 PM
0 · Reply
caronte
caronte Jun. 29 at 6:56 PM
$FDMT hi all, I was monitoring the up and dows to re-enter at a lower level (like 6-7) but apparently i did not time it well. Would you guys jump in at 13? On the long term I have no doubts, I believe in this company but in the short term (for a swing) it is damn hard to optimize timing. Thankyou and @ReturnOfEsquire how are you?
1 · Reply
Helpmrwizard
Helpmrwizard Jun. 29 at 4:54 PM
$FDMT looking interesting
0 · Reply
InvestorWisdom
InvestorWisdom Jun. 24 at 3:53 AM
$CMPS updated chart: It did not close under the 10ema for a couple months on the last run… and it has potentially regained it today. The low of the day was right on it after closing above 4 days ago… It might still be forming a base and need more time, but this could be the start of a new uptrend, cause IMO money is rotating into Biotech, which is one of the top near term sectors that will benefit significantly from the growth of AI… and many biotech stocks have been forming bottom and continuation bases = institutions accumulating  Compass has the potential to be a BIG one. The White House is pushing psychedelics and no one else is closer + Compass potential is massive and not fairly represented in this $1.7b valuation imo + Robert F Kennedy is pro psychedelics If they all want psychedelics approved for veterans etc it’s gonna get approved imo. There’s no significant side effects so what is the risk if it’s working with so many peeps?… and approval could happen as soon as this year I have already posted charts for $IOVA $AUPH $INSM $FDMT … heres 3 screenshots, i included XBI to show the sector base breakout + some key DD...
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 24 at 12:07 AM
$FDMT Huge insider sell announced. David Kirn sold 114,746 shares for $1,200,851.31. I'm sure Scott Bizily will be selling, too.
0 · Reply
Latest News on FDMT
4D Molecular completes enrollment in 4FRONT-2 trial

2026-06-29T12:15:46.000Z - 2 days ago

4D Molecular completes enrollment in 4FRONT-2 trial


4D Molecular Therapeutics Transcript: AGM 2026

Jun 17, 2026, 1:30 PM EDT - 14 days ago

4D Molecular Therapeutics Transcript: AGM 2026


4DMT Announces New Employment Inducement Grants

Jun 12, 2026, 4:05 PM EDT - 19 days ago

4DMT Announces New Employment Inducement Grants


4DMT to Participate in Upcoming Investor Conferences

May 27, 2026, 8:00 AM EDT - 5 weeks ago

4DMT to Participate in Upcoming Investor Conferences


4D Molecular files $400M mixed securities shelf

2026-05-07T22:48:23.000Z - 7 weeks ago

4D Molecular files $400M mixed securities shelf


4D Molecular Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

4D Molecular Therapeutics Quarterly report: Q1 2026


4D Molecular Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 7 weeks ago

4D Molecular Therapeutics Earnings release: Q1 2026


4D Molecular Therapeutics Slides: Corporate presentation

May 7, 2026, 7:00 AM EDT - 7 weeks ago

4D Molecular Therapeutics Slides: Corporate presentation


4D Molecular Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing


4D Molecular Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

4D Molecular Therapeutics Proxy statement: Proxy filing


4D Molecular assumed with a Buy at Jefferies

2026-03-30T13:08:58.000Z - 3 months ago

4D Molecular assumed with a Buy at Jefferies


4D Molecular Therapeutics Annual report: Q4 2025

Mar 18, 2026, 5:00 PM EDT - 3 months ago

4D Molecular Therapeutics Annual report: Q4 2025


4D Molecular Therapeutics Earnings release: Q4 2025

Mar 18, 2026, 5:00 PM EDT - 3 months ago

4D Molecular Therapeutics Earnings release: Q4 2025


4D Molecular Therapeutics Slides: Corporate presentation

Mar 18, 2026, 7:00 AM EDT - 3 months ago

4D Molecular Therapeutics Slides: Corporate presentation


4DMT to Participate in Upcoming Investor Meetings

Mar 16, 2026, 8:00 AM EDT - 3 months ago

4DMT to Participate in Upcoming Investor Meetings


4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial

2026-02-09T13:26:19.000Z - 5 months ago

4D Molecular completes enrollment for 4FRONT-1 Phase 3 trial


4D Molecular assumed with an Overweight at Barclays

2026-01-27T21:27:44.000Z - 5 months ago

4D Molecular assumed with an Overweight at Barclays


4D Molecular announces employment inducement grants

2026-01-19T18:35:06.000Z - 5 months ago

4D Molecular announces employment inducement grants


4D Molecular Therapeutics Transcript: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Transcript: Study Result


4D Molecular Therapeutics Press release: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Press release: Study Result


4D Molecular Therapeutics Slides: Study Result

Dec 17, 2025, 8:00 AM EST - 7 months ago

4D Molecular Therapeutics Slides: Study Result


4DMT to Participate in 8th Annual Evercore Healthcare Conference

Nov 20, 2025, 8:00 AM EST - 7 months ago

4DMT to Participate in 8th Annual Evercore Healthcare Conference


4D Molecular names Kristian Humer as CFO

2025-11-17T11:10:33.000Z - 8 months ago

4D Molecular names Kristian Humer as CFO


4DMT Appoints Kristian Humer as Chief Financial Officer

Nov 17, 2025, 6:00 AM EST - 8 months ago

4DMT Appoints Kristian Humer as Chief Financial Officer


4D Molecular price target raised to $32 from $26 at RBC Capital

2025-11-11T14:25:18.000Z - 8 months ago

4D Molecular price target raised to $32 from $26 at RBC Capital


4D Molecular price target lowered to $33 from $38 at Barclays

2025-11-11T10:25:26.000Z - 8 months ago

4D Molecular price target lowered to $33 from $38 at Barclays


4D Molecular Therapeutics Quarterly report: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

4D Molecular Therapeutics Quarterly report: Q3 2025


4D Molecular Therapeutics Earnings release: Q3 2025

Nov 10, 2025, 8:00 AM EST - 8 months ago

4D Molecular Therapeutics Earnings release: Q3 2025


4D Molecular Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

4D Molecular Therapeutics Quarterly report: Q2 2025


4D Molecular Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 8:00 AM EDT - 11 months ago

4D Molecular Therapeutics Earnings release: Q2 2025


4D Molecular Therapeutics Slides: FY 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Slides: FY 2025

May 14, 2025, 5:20 PM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Earnings release: Q1 2025


4D Molecular Therapeutics Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

4D Molecular Therapeutics Quarterly report: Q1 2025


4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing


4D Molecular Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

4D Molecular Therapeutics Proxy statement: Proxy Filing


4D Molecular Therapeutics Slides: FY 2025

Mar 11, 2025, 10:00 AM EDT - 1 year ago

4D Molecular Therapeutics Slides: FY 2025


4D Molecular Therapeutics Annual report: Q4 2024

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Annual report: Q4 2024


4D Molecular Therapeutics Earnings release: Q4 2024

Feb 28, 2025, 4:00 PM EST - 1 year ago

4D Molecular Therapeutics Earnings release: Q4 2024


4D Molecular Therapeutics Transcript: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Transcript: Study Result


4D Molecular Therapeutics Press release: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Press release: Study Result


4D Molecular Therapeutics Slides: Study Result

Feb 10, 2025, 8:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: Study Result


4D Molecular Therapeutics Slides: FY 2024

Nov 19, 2024, 7:00 AM EST - 1 year ago

4D Molecular Therapeutics Slides: FY 2024


LMARB
LMARB Jul. 1 at 3:19 PM
$FDMT wonder what this will avg after 2 year follow up presentation in 3 weeks
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:52 PM
$FDMT Got cute and swung one too many times...oh well. I'll take a long position once this cools off.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 4:04 PM
$FDMT RSI of 77? It's been a long time since it's seen that kind of strength.
0 · Reply
Doozio
Doozio Jun. 30 at 2:20 AM
$FDMT ENTA 🐒🍌🧠⏰♾️
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 30 at 12:04 AM
$FDMT https://www.statnews.com/2026/06/29/vijay-kumar-exits-fda-office-of-therapeutic-products/
1 · Reply
StonkMethod
StonkMethod Jun. 29 at 6:58 PM
0 · Reply
caronte
caronte Jun. 29 at 6:56 PM
$FDMT hi all, I was monitoring the up and dows to re-enter at a lower level (like 6-7) but apparently i did not time it well. Would you guys jump in at 13? On the long term I have no doubts, I believe in this company but in the short term (for a swing) it is damn hard to optimize timing. Thankyou and @ReturnOfEsquire how are you?
1 · Reply
Helpmrwizard
Helpmrwizard Jun. 29 at 4:54 PM
$FDMT looking interesting
0 · Reply
InvestorWisdom
InvestorWisdom Jun. 24 at 3:53 AM
$CMPS updated chart: It did not close under the 10ema for a couple months on the last run… and it has potentially regained it today. The low of the day was right on it after closing above 4 days ago… It might still be forming a base and need more time, but this could be the start of a new uptrend, cause IMO money is rotating into Biotech, which is one of the top near term sectors that will benefit significantly from the growth of AI… and many biotech stocks have been forming bottom and continuation bases = institutions accumulating  Compass has the potential to be a BIG one. The White House is pushing psychedelics and no one else is closer + Compass potential is massive and not fairly represented in this $1.7b valuation imo + Robert F Kennedy is pro psychedelics If they all want psychedelics approved for veterans etc it’s gonna get approved imo. There’s no significant side effects so what is the risk if it’s working with so many peeps?… and approval could happen as soon as this year I have already posted charts for $IOVA $AUPH $INSM $FDMT … heres 3 screenshots, i included XBI to show the sector base breakout + some key DD...
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Jun. 24 at 12:07 AM
$FDMT Huge insider sell announced. David Kirn sold 114,746 shares for $1,200,851.31. I'm sure Scott Bizily will be selling, too.
0 · Reply
InvestorWisdom
InvestorWisdom Jun. 23 at 6:18 PM
$FDMT weekly chart… bought the trendline break earlier. Many biotech stocks have strong continuation bases and bottom formations
0 · Reply
NeonRaider
NeonRaider Jun. 23 at 6:03 PM
$FDMT 13-15$ next up
0 · Reply
focafoca99
focafoca99 Jun. 22 at 8:36 PM
$FDMT conducted its 2026 annual meeting, electing three new directors and ratifying its auditor.
0 · Reply
morningmover
morningmover Jun. 22 at 6:20 PM
$FDMT looking great
0 · Reply
Quantumup
Quantumup Jun. 22 at 1:49 PM
H.C. Wainwright (a/o 6/18)⬆️ $OCUL-$25,⬆️PoS & reit'd Buy after Ocular hosted its Investor Day in NYC, in which the company discussed the outcome of its Type C meeting with the FDA and the KOLs endorsed the adoption of AXPAXLI. $EYPT SRZN REGN $FDMT RHHBY KOD Here's what else H.C. Wainwright had to say: https://x.com/Quantumup1/status/2069054846682931637?s=20
0 · Reply
AtariLynx
AtariLynx Jun. 11 at 4:43 PM
$FDMT come on!
0 · Reply
AtariLynx
AtariLynx Jun. 11 at 4:42 PM
$FDMT Up! Up! Up!
0 · Reply
McMillion1
McMillion1 Jun. 5 at 6:23 PM
$FDMT why is this dropping?
1 · Reply
Following_the_trend
Following_the_trend Jun. 3 at 2:28 PM
$FDMT Back on W/L for another round.
0 · Reply
ebodonicus
ebodonicus Jun. 2 at 2:55 AM
$FDMT Man if I wasn’t so broke, I’d be making so much money off this one. This stock really be swangin’
0 · Reply
BioRich
BioRich Jun. 1 at 12:39 PM
$EWTX $ABAT $FDMT $VNRX $KEEL Looking damn good. Nice move today $EWTX. The gains we were expecting is starting to happen (nice pop today) and looks like it'll continue to go. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
McMillion1
McMillion1 May. 29 at 8:08 PM
$FDMT This should be at least $20
1 · Reply